tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

JP:4591 Stock Latest News

Ribomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data
Company AnnouncementsRibomic Files Patent for High-Activity Eye-Disease Aptamer RBM-006 After Positive Diabetic Retinopathy Data
19d ago
4591
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
PremiumCompany Announcements
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
2M ago
4591
Ribomic Inc. Reports Six-Month Financial Results with No Revenues
PremiumCompany Announcements
Ribomic Inc. Reports Six-Month Financial Results with No Revenues
3M ago
4591
RIBOMIC Reports Successful Phase II Trial for Achondroplasia Treatment
PremiumCompany Announcements
RIBOMIC Reports Successful Phase II Trial for Achondroplasia Treatment
4M ago
4591
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
PremiumCompany Announcements
RIBOMIC Reports Positive Phase 2 Trial Results for Achondroplasia Treatment
4M ago
4591
RIBOMIC Discovers New Treatment Potential for Diabetic Retinopathy
PremiumCompany AnnouncementsRIBOMIC Discovers New Treatment Potential for Diabetic Retinopathy
4M ago
4591
RIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
Premium
Company Announcements
RIBOMIC Reports Sustained Efficacy of Umedaptanib Pegol in Achondroplasia Trial
6M ago
4591
Ribomic Inc. Reports Continued Losses in Q1 2025
Premium
Company Announcements
Ribomic Inc. Reports Continued Losses in Q1 2025
6M ago
4591
RIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
PremiumCompany Announcements
RIBOMIC to Launch Phase III Trial for Achondroplasia Drug in 2026
6M ago
4591
Ribomic Inc. Reports Continued Net Loss for Fiscal Year 2025
PremiumCompany Announcements
Ribomic Inc. Reports Continued Net Loss for Fiscal Year 2025
9M ago
4591
Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
PremiumCompany Announcements
Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
12M ago
4591
Ribomic Sees Reduced Losses in Latest Financial Report
PremiumCompany Announcements
Ribomic Sees Reduced Losses in Latest Financial Report
1y ago
4591
Ribomic Inc. Reports Quarterly Loss, Stable Assets
PremiumCompany AnnouncementsRibomic Inc. Reports Quarterly Loss, Stable Assets
1y ago
4591
RIBOMIC Advances Pediatric Achondroplasia Treatment Study
Premium
Company Announcements
RIBOMIC Advances Pediatric Achondroplasia Treatment Study
2y ago
4591

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >